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Abstract: Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central
nervous system (CNS) which is associated with lower life expectancy and disability. The experimental
antigen-induced encephalomyelitis (EAE) in mice is a useful animal model of MS, which allows
exploring the etiopathogenetic mechanisms and testing novel potential therapeutic drugs. A new
therapeutic paradigm for the treatment of MS was introduced in 2010 through the sphingosine
1-phosphate (S1P) analogue fingolimod (FTY720, Gilenya®), which acts as a functional S1P1 antagonist
on T lymphocytes to deplete these cells from the blood. In this study, we synthesized two novel
structures, ST-1893 and ST-1894, which are derived from fingolimod and chemically feature a
morpholine ring in the polar head group. These compounds showed a selective S1P1 activation
profile and a sustained S1P1 internalization in cultures of S1P1-overexpressing Chinese hamster
ovary (CHO)-K1 cells, consistent with a functional antagonism. In vivo, both compounds induced
a profound lymphopenia in mice. Finally, these substances showed efficacy in the EAE model,
where they reduced clinical symptoms of the disease, and, on the molecular level, they reduced the
T-cell infiltration and several inflammatory mediators in the brain and spinal cord. In summary,
these data suggest that S1P1-selective compounds may have an advantage over fingolimod and
siponimod, not only in MS but also in other autoimmune diseases.
Keywords: ST-1893; ST-1894; morpholino analogues of fingolimod; sphingosine
1-phosphate; immunomodulator; lymphopenia; multiple sclerosis; experimental antigen-induced
encephalomyelitis
1. Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune disease of the
central nervous system (CNS), which affects more than 2.3 million people worldwide, mostly young
adults. The pathological features of MS include the formation of plaques (lesions) in the brain and
spinal cord, where inflammation, demyelination, gliosis (scarring), axonal injury, and axonal loss
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occur [1]. Although it is not considered as a fatal disease, it is associated with lower life expectancy
and disability that affects the quality of life [2]. A new therapeutic paradigm for the treatment of
MS was introduced in 2010 and featured a modulation of the sphingosine 1-phosphate receptor 1
(S1P1) signaling by using fingolimod (FTY720, Gilenya®). Fingolimod desensitizes S1P1 in T cells,
blocking their egress from lymph nodes and leading to lymphopenia [3]. After the approval of
fingolimod, which is a non-selective S1PR modulator, the search for structures with better selectivity,
potency, pharmacokinetic properties, effectiveness for other autoimmune and inflammatory diseases,
and fewer adverse effects was boosted [4]. At the beginning of 2020, two additional drugs, siponimod
(BAF312, Mayzent®) and ozanimod (RPC-1063, Zeposia®), were approved by the European Medicines
Agency for oral treatment of patients with relapsing–remitting MS (ozanimod) or the active secondary
progressive form of MS (siponimod). Interestingly, siponimod and ozanimod, compared to fingolimod,
exhibit selective affinity for S1P1 and S1P5, leading to a lower risk of adverse events [5], which proves
the rationale for selective targeting of the S1P receptors.
The five S1P receptor subtypes belong to the family of G-protein-coupled receptors (GPCRs),
which are present on the cell surface where they bind with high affinity to secreted S1P and mediate
an “inside-out” signaling [6]. Versatile cellular responses are elicited upon binding of the receptors
with S1P as their cognate ligand, including proliferation, survival, invasion, adhesion, and migration,
pertaining to the indispensability of S1P for the normal functioning of the cardiovascular, nervous,
immune, and other systems [4]. S1P and S1P receptors also regulate pathophysiological processes,
including inflammatory mediator synthesis, tissue remodeling, and angiogenesis, contributing to the
pathogenesis of various diseases; thus, they may serve as targets for prevention or treatment [4].
S1P1, S1P2, and S1P3 are ubiquitously expressed, while S1P4 and S1P5 have a restricted expression
in the immune compartments and in the CNS, respectively. Lack of S1P2/3/4 or S1P5 in mice does not
produce an apparent phenotype; however, lack of S1P1 in mice results in embryonic lethality due to an
inefficient process of vascular maturation and consequent hemorrhage, pointing to a non-redundant
role of S1P1 in the vascular system [7]. S1P1 also plays a significant physiological role as a key regulator
of lymphocyte trafficking, and the main pharmacodynamic effect of fingolimod and siponimod
lays in their ability to induce a persistent internalization of S1P1 in lymphocytes and subsequent
lymphopenia [8].
Critical for the lymphocyte trafficking is a S1P gradient, which exists among the plasma,
the interstitial space of secondary lymphoid tissues, and the lymph, and which is sensed by the
lymphocytes through S1P1 [9]. As they move from spaces with high to low S1P concentrations,
their desensitized S1P1 is recycled back to the cell surface and can become again responsive to S1P [10].
Fingolimod and siponimod also induce S1P1 internalization; however, in contrast to S1P, the receptor
is irreversibly degraded in the proteasome and does not recycle back to the cell surface which reduces
its membrane expression, a phenomenon known as “functional antagonism” [11]. That way, the egress
of lymphocytes, particularly naïve and central memory T cells, is hindered, while effector memory T
cells are spared, resulting in an overall preferential reduction of the pathogenic immune responses
and sparing large parts of protective immunity in multiple sclerosis patients [12]. As autoaggressive T
cells are involved in the pathology of many autoimmune diseases in addition to MS, such as Crohn’s
disease, ulcerative colitis, and rheumatoid arthritis, a wider therapeutic use for S1PR modulators may
be envisioned.
Apart from S1P1, fingolimod also targets S1P3, S1P4, and S1P5. While S1P5 is thought to mediate
beneficial effects in the CNS, S1P3 is rather involved in adverse reactions’ signaling [4], such as
vasoconstrictive events and hypertension [13]. The role of S1P4 in physiological processes is still poorly
understood and, therefore, the effects of fingolimod mediated by S1P4 are vague. This highlights the
need for developing compounds with a narrow S1PR selectivity profile which will allow tackling a
specific pathology while having a more predictable spectrum of adverse reactions.
In this study, we present two novel compounds derived from fingolimod, ST-1893 and ST-1894,
which chemically feature slight alterations in the polar head group by introducing a substituted
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morpholino ring (Figure 1), and this results in a selectivity toward S1P1. Both compounds were full
agonists at S1P1, although less potent than S1P, and they also exhibited functional antagonistic activity
as shown by a sustained internalization in a cell culture of S1P1-overexpressing Chinese hamster
ovary (CHO)-K1 cells. In vivo, they exerted a lymphopenic effect in mice and were efficacious in an
experimental antigen-induced encephalomyelitis (EAE) model, where they reduced the motor deficits,
improved the body weight, and prevented the development of disease with the highest clinical score.
Due to their S1P1-selective nature, they possibly exhibit fewer adverse effects and have an advantage
over fingolimod and siponimod, not only in MS but also in other autoimmune diseases.
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We further studied whether ST-1893 and ST-1894 could act as antagonists. For this, cells were
stimulated with a fixed concentration of S1P in the presence of increasing concentrations of either
ST-1893 or ST-1894. However, no reduction of S1P-stimulated p42/p44-MAPK activation was detected,
excluding a direct antagonistic effect of ST-1893 and ST-1894 (Figure 2A). Furthermore, ST-1893-
and ST-1894-stimulated p42/p44-MAPK activation was completely abolished by pretreatment with
the competitive S1P1 antagonist NIBR-0213 (Figure 3A) [16] and by pertussis toxin (Figure 3B),
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cells were pretreated for 15 min with NIBR-0213 (NIBR, 1 µM) (A) or for 18 h with pertussis toxin
(PTX, 100 ng/mL) (B) prior to stimulation for 10 min with either vehicle (dimethyl sulfoxide (DMSO))
ST-1893, or ST-1894 (both at 3 µM). Protein extracts were prepared, separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to Western blot analysis as described in Section 4. Membranes were
probed with hospho- and total-p42/p44-MAPK, and representative samples out of three independent
experiments are shown.
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substantially differe t S1P concentrations, whi h are very high in the blood and low in he tissue.
High concentrations of S1P are supposed to induce desensitization of S1P1, and, as the concentration
of S1P drops, S1P1 is recycled back to the cell surface and becomes again sensitive to S1P [10].
The initial phase of fingolimod-induced internalization resembles that of S1P; however, the subsequent
mechanism is unique for fingolimod as it does not dissociate from the receptor, and the whole
fingolimod–S1P1 receptor complex is sorted for degradation, resulting in receptor depletion on the
surface [17]. Since fingolimod is known to induce sustained internalization and, thus, desensitization of
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S1P1, described as functional antagonism, we further tested whether ST-1893 and ST-1894 exert the same
functional antagonism. To this end, an in situ ELISA was established to detect cell surface-expressed
Myc-tagged S1P1. Stimulation of CHO-S1P1 cells for 3 h, with either S1P or the ST compounds,
resulted in a 50–75% reduction of cell surface S1P1 (Figure 4A). When cells were stimulated for
3 h and a subsequent washout period of 22 h, a complete recovery of S1P1 in the S1P-stimulated
group was observed, pointing to an efficient recycling process (Figure 4B). Conversely, in ST-1893- or
ST-1894-treated samples, cell surface S1P1 remained low, suggesting a persistent internalization.
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desensitization. (A, B) Starved confluent CHO-K1 cells overexpressing N-Myc-tagged S1P1 receptor in
24-well plates were stimulated with equimolar concentrations (3 µM) of S1P, ST-1893, ST-1894, or DMSO
control for 3 h (A), or 3 h followed by 22 h in serum-free conditions for recovery (B). Cells were fixed
and further processed as explained in Section 4. Results are expressed as a percentage of control and
are means ± SD (n = 3); **** p < 0.0001 compared to DMSO-treated control samples. (C) Starved
confluent CHO-S1P1 cells were stimulated with 3 µM S1P, ST-1893, ST-1894, or DMSO (control) for 3 h
followed by 22 h washout in serum-fre conditions, and re- timulation for 10 min with 3 µM S1P.
Cell lysates were subjected to Western blot analysis and membranes were probed with phospho- and
total p42/p44-MAPK antibodies. Results are expressed as a percentage of control cells and are depicted
as means ± SD (n = 3); *** p < 0.001, **** p < 0.0001.
To further prove that sustained S1P1 internalization also leads to a sustained downregulation
of S1P1 signaling, after the washout period, cells were re-stimulated with a new pulse of S1P for
10 min and taken for MAPK activation. Data showed that prolonged pre-treatment with ST-1893 or
ST-1894, but not S1P, caused a downregulation of S1P signaling. As seen in Figure 4C, S1P1 is similarly
activated in the S1P-treated group as in the control, suggesting that, within the 22 h of recovery period,
S1P1 was recycled to the cell surface and could be stimulated again by S1P. On the other hand, due to
the long-term internalization and desensitization, without receptor recycling, ST-1893 and ST-1894
groups had decreased p42/p44-MAPK activation after a new pulse of S1P stimulation.
In a further step to analyze the binding of ST compounds to the ligand-binding pocket of S1P1
and to determine the possibly interacting amino acids, a homologous S1P1 model was developed on
the basis of the X-ray structure [18]. To generate an activated S1P1 model, the adrenergic receptor
was replaced by the homologous S1P1 using an established β2-adrenergic receptor–arrestin complex
(Figure S1, Supplementary Materials). This approach allows the development of homologous models
of activated GPCR proteins [19,20]. The ligands were charged by applying the molecular operating
environment (MOE) program and docking experiments were performed. Indeed, both molecules,
ST-1893 (Figure S2A, Supplementary Materials) and ST-1894 (Figure S2B, Supplementary Materials)
fitted well into the binding pocket as shown in the two- (Figure S2, Supplementary Materials) and
the three-dimensional models (Figure S3, Supplementary Materials). Moreover, the docking results
and energy minimization calculations predicted an interaction with S1P1 (Table S1, Supplementary
Materials). The morpholino-group of ST-1893 and ST-1894 and their hydroxymethyl substituents
interacted with Lys-34 (H-donor), Tyr-29 (H-donor), Glu-121 (H-acceptor), and Glu-294 (H-acceptor).
These interactions with specific amino-acid residues suggested that both ST-1893 and ST-1894 may
exert S1P1 agonist activity. The docking score for ST-1893 corresponds approximately to ST-1071 [15];
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however, due to the larger volume of ST-1893, we predicted that dissociation from the receptor would
be more hampered, leading to a higher activity.
Interestingly, docking experiments and calculation of binding energies indicated that a more
favorable interaction with S1P1 occurs when both substances, ST-1893 and ST-1894, are phosphorylated
(Table S1, Supplementary Materials). The binding energy of ST-1893 increased from −112.80 kcal/mol of
the non-phosphorylated form to −150.15 kcal/mol when the molecule was phosphorylated. In analogy,
ST-1894 shows an enhanced binding energy of the phosphorylated molecule as there was an increase
from−128.09 kcal/mol to−156.47 kcal/mol. FTY720-phosphate showed in the same docking experiments
a binding energy of −141.98 kcal/mol. The oxygen and a carbon from the morpholino-group from
ST-1893-phosphate and ST-1894-phosphate both interacted with Asn-101 (Figure S2A,B, Supplementary
Materials). The phosphorylated head of both compounds interacts with the amino acids Tyr-29
(H-donor), Lys-34 (H-donor), and Arg-120 (H-donor) similar to S1P. With the amino acid Leu-297
there is an aren-H interaction with the phenyl ring. ST-1893-phosphate interacts additionally with
Phe-125 (aren-H).
The functional antagonism of fingolimod in vivo manifests as blocked egress from secondary
lymphoid tissues and a subsequent drop in the number of lymphocytes in the blood. To confirm
the functional antagonistic properties of ST-1893 and ST-1894 on S1P1 in vivo, wild-type C57BL/6J
mice were injected intraperitoneally with 5 mg/kg of compounds or dimethyl sulfoxide (DMSO) and,
after 24 h, the number of lymphocytes in blood was measured. Results show that, at the dose of
5 mg/kg of ST-1893 or ST-1894, a drop in blood lymphocytes of 58% and 64%, respectively, occurred,
confirming their immunosuppressive potential (Figure 5).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 18 
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Figure 5. Effect of ST-1893 and ST-1894 on the number of lymphocytes in mice. C57BL/6J wild-type (wt)
mice were injected intraperitoneally with 5 mg/kg ST-1893, ST-1894, or DMSO in phosphate-buffered
saline (PBS) as a control, and, after 24 h, blood was collected in ethylenediaminetetraacetic acid
(EDTA)-K3-coated microvettes with cardiac puncture under deep terminal isoflurane-induced
anesthesia. The number of lymphocytes per mL was assessed as explained in Section 4 and is
presented as means ± SD (n = 4).
In a next step, to evaluate the efficacy of ST-1893 and ST-1894 in a model of autoimmune
inflammatory disease, we conducted an active myelin oligodendrocyte glycoprotein (MOG)-induced
EAE experiment in C57BL/6J mice, in which ST-1893 and ST-1894 were given prophylactically and
daily starting at day 5 post immunization. In vehicle-treated control mice, the first motor symptom,
i.e., a limp tail, appeared at approximately day 10, and, as the disease progressed, the motor signs
in the vehicle-treated group aggravated and mice acquired hind leg paraplegia and loss of lower
body control. ST-1893- and ST-1894-treated mice showed a much milder clinical picture, with reduced
motor deficits (Figure 6A), the highest reached clinical score (Figure 6B), and improved body weight
(Figure 6C). In these observations, there was a slight advantage of ST-1894 over ST-1893 at equal dose,
which could be associated with the more potent effect on the S1P1 internalization and lymphocyte
count. At day 21 post immunization, mice were sacrificed, and lymphocyte analysis in blood showed
only a pattern of decrease in the ST-1893- and ST-1894-treated groups (Figure 6D), which contrasts
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the data obtained from healthy mice, where the depletion of blood lymphocytes was apparent and
statistically significant. We attribute this discrepancy to the already low level of lymphocytes in the
control group, which is in agreement with previous studies and the fact that the development of EAE
itself is associated with a marked reduction in peripheral blood lymphocyte count [16,21].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 18 
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Figure 6. Effect of ST-1893 and ST-1894 on experimental antigen-induced encephalomyelitis (EAE)
disease course. EAE was induced in C57BL/6J wt mice and, starting from day 5 until day 20 post
immunization, they were injected with ST-1893, ST-1894, or DMSO dissolved in PBS at 5 mg/kg,
as explained in Section 4. Graph in (A) represents the daily clinical score based on a four-point scoring
system, and the inset graph presents the area under the curve (AUC) value from the scores from day
0 until day 21. The maximal clinical score reached for each individual mouse is presented in graph
(B). Graph in (C) shows the weight change based on the weight at day 0 set as 0%, with the respective
AUC calculation in inset. Results (A–C) are presented as means ± standard errors of the mean (SEM);
* p < 0.05, ** p < 0.01, statistically significant when compared to the DMSO control EAE group (n = 10,
DMSO; n = 5, ST-1893; n = 5, ST-1894). (D) Blood was collected at day 21 in EDTA-K3-coated microvettes
with cardiac puncture, and the number of lymphocytes per mL was measured as explained above and
is presented as means ± SD (n = 11, DMSO; n = 5, ST-1893; n = 4, ST-1894).
Nevertheless, tissue analysis showed a reduced expression of the T-cell marker cluster of
differentiation 3 (CD3) (Figure 7A) in the CNS of ST-1893- and ST-1894-treated mice, as well as reduced
messenger RNA (mRNA) expression of the inflammatory markers interleukin (IL)-1β (Figure 7B) and
vascular cell adhesion molecule (VCAM)-1 (Figure 7D), as well as of the astroglial marker of scarring,
glial fibrillary acidic protein (GFAP) (Figure 7C).
Since fingolimod is a prodrug and is known to strictly depend on phosphorylation by sphingosine
kinase (SK)-2, but not SK-1, for therapeutic activity, we further tested whether ST-1893 and ST-1894
would also require phosphorylation by SK-2 for activity.
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were used as positive controls for biotransformation by SK-2. Data in Figure 8 show that inhibition 
of SK-2 completely abolishes the activation of p42/p44-MAPK through the S1P1 receptor by 
fingolimod and confirms that preceding phosphorylation is needed for agonistic activity. In contrast, 
since S1P is already active, it is not affected by the inhibition of SK-2 and demonstrates no difference 
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Figure 7. Analysis of the messenger RNA (mRNA) expression of several markers in the central
nervous system (CNS) of EAE mice. CNS samples extracted from perfused EAE mice on day 21
were homogenized as explained in Section 4 and were taken for extraction of RNA. Complementary
DNA (cDNA) synthesis and quantitative PCR analysis were performed, and primers for cluster of
differentiation 3 (CD3) (A), interleukin (IL)-1β (B), glial fibrillary acidic protein (GFAP) (C), and vascular
cell adhesion molecule (VCAM)-1 (D) were used. Results are presented as a percentage of DMSO
control and are means ± SEM (n = 8, DMSO; n = 5, ST-1893; n = 2–3, ST-1894).
To this end, in vitro assays were first conducted in CHO-S1P1 cells pretreated with the SK-2
inhibitor SLM6031434, after which they were stimulated with ST-1893 or ST-1894. S1P and fingolimod
were used as positive controls for biotransformation by SK-2. Data in Figure 8 show that inhibition of
SK-2 completely abolishes the activation of p42/p44-MAPK through the S1P1 receptor by fingolimod
and confirms that preceding phosphorylation is needed for agonistic activity. In contrast, since S1P
is already active, it is not affected by the inhibition of SK-2 and demonstrates no difference in the
activation of S1P1 in the presence or absence of SLM6031434. ST-1893 and ST-1894 behaved like
fingolimod and lost their S1P1-activating abilities in the presence of the inhibitor.
To investigate further the possible prodrug characteristics of ST-1893 and ST-1894, we used
SK-2 knockout mice and analyzed for lymphopenia reaction after injection of ST-1893 and ST-1894.
The number of lymphocytes in peripheral blood after 24 h was similar between the groups, with a
tendency of decrease by ST-1894, although not significant (Figure 9). These data support the modeling
study confirming that the phosphorylated structures are more potent.
Finally, in an EAE experiment using SK-2 knockout mice, ST-1893-treated mice conferred no
protection from developing the disease, while ST-1894-treated mice bore a partial protection. This was
observed not only in terms of their mean daily clinical score (Figure 10A), but also in their weight
(Figure 10B) and maximal clinical score (Figure 10C). Altogether, these data point to a transformation
of ST-1893 and ST-1894 by SK-2 in order to reach their full immunomodulatory effectiveness in vivo.
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coated microvettes with cardiac puncture under deep terminal isoflurane-induced anesthesia. The 
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Finally, in an EAE experiment using SK-2 knockout mice, ST-1893-treated mice conferred no 
protection from developing the disease, while ST-1894-treated mice bore a partial protection. This 
was observed not only in terms of their mean daily clinical score (Figure 10A), but also in their weight 
Figure 8. Effect of SK-2 inhibition on S1P, fingolimod, ST-1893, and ST-1894 on S1P1-induced
p42/p44-MAPK phosphorylation. Starved confluent CHO-S1P1 cells were pre-stimulated for 2 h
with the SK-2 inhibitor SLM6031434 (1 µM), after which they were stimulated with 100 nM S1P, 1 µM
fingolimod (FTY), 1 µM ST-1893, or 1 µM ST-1894 for 10 min. Cells were harvested for usual Western blot
analysis, and membranes were probed with phospho- and total-p42/p44-MAPK antibodies. Presented
blots are representatives of three independent experiments.
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Figure 9. Effect of SK-2 deficiency on the lymphocyte number after ST-1893 and ST-1894 administration
in vivo. C57BL/6J SK-2 knockout mice were injected intraperitoneally with 5 mg/kg ST-1893, ST-1894,
or DMSO in PBS as a control, and, after 24 h blood, was collected in EDTA-K3-coated microvettes with
cardiac puncture under deep terminal isoflurane-induced anesthesia. The number of lymphocytes per
mL was assessed as explained in Section 4 and is presented as means ± SD (n = 13 for DMSO; n = 11 for
ST-1893; n = 9 for ST-1894).
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voluminous aryl chain in the para-position [22], we hypothesized that they would fit in the ligand-
binding pocket of the S1P1 receptor and exert potent agonistic conformational change. Indeed, 
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on the other hand, a good S1P1 agonistic activity was predicted. Next, we fully characterized these 
compounds for agonistic and antagonistic activity on each of the S1P receptor subtypes and applied 
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development of EAE with the highest clinical score (Figure 6A–C). This was accompanied by reduced 
Figure 10. Effect of ST-1893 and ST-1894 on EAE disease course in SK-2 knockout mice. EAE was
induced in C57BL/6J SK-2 knockout mice and, starting from day 5 until day 20 post immunization,
they were injected with ST-1893, ST-1894, or DMSO dissolved in PBS at 5 mg/kg as explained in
Section 4. Graph in (A) represents the daily clinical score based on a four-point scoring system, and the
inset graph presents the area under the curve (AUC) value from the scores from day 0 until day 21.
Graph in (B) shows the weight change based on the weight at day 0 set as 0%, with the respective AUC
calculation in inset. The maximal clinical score reached for each individual mouse is presented in graph
(C). Results are presented as means ± SEM (n = 10, DMSO; n = 5, ST-1893; n = 8, ST-1894); * p < 0.05,
** p < 0.01, statistically significant when compared to the DMSO control EAE group.
3. Discussions
One decade after fingolimod gained access to the market as the first S1P receptor modulator for
the treatment of multiple sclerosis, the therapeutic potential of the S1P–S1PR axis signaling took center
stage in sphingolipid research. Fingolimod is an unselective modulator of four of the five S1P receptors;
therefore, one of the focuses of second-generation modulators is placed on structures with narrower
S1P receptor targeting, thereby achieving fewer unspecific adverse effects.
In this study, we report the synthesis and validation of two novel selective modulators of the S1P1
receptor, ST-1893 and ST-1894, which chemically are morpholino-derivatives of fingolimod (Figure 1).
Based on their chemical structures, namely, the presence of a polar head group and a voluminous
aryl chain in the para-position [22], we hypothesized that they would fit in the ligand-binding pocket
of the S1P1 r ceptor and exert potent agonistic c nformational change. Indeed, molecular modeling
using a homology of S1P1 in its active form showed that the docking results and binding strengths
fully correspond to the theory of S1P–S1P1 interactions (Figure S1, Supplem ntary Mat rials). On the
b sis of the good establishment f hydrogen bo ds between the substituted morpholino-moiety on
one hand and the surrounding amino-acid residues from the binding pocket on the other hand, a good
S1P1 agonistic activity was predicted. Next, we fully characterized these compounds for agonistic and
antagonistic activity on each of the S1P receptor subtypes and applied them in vivo in healthy mice
with EAE as a model of MS. Both substances showed in vivo efficacy in the EAE model where they
reduced the motor deficits, improved the body weight, and prevented the development of EAE with
the highest clinical score (Figure 6A–C). This was accompanied by reduced T-cell infiltration in the CNS
and reduced expression of several mediators which have an aggravating role in the neuroinflammatory
process, which explains the ameliorated phenotype (Figure 7). In vitro, they potently activated the
S1P1 receptor and acted as agonists at early time-points (Figure 2), while, later on, they downregulated
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the surface expression of the receptor (Figure 4A–C), which accounts for their lymphopenic effect in
mice (Figure 5).
Our group previously characterized oxazolo–oxazolo-derivatives of fingolimod, denoted ST-968
and ST-1071, which have a dual S1P1+3 selectivity and turned out to be as efficient as fingolimod
in vitro in cell cultures, as well as in vivo in reducing disease symptoms of EAE in mice [15].
The primary mechanism of action, for our novel morpholino-derivatives, as well as for the
oxazolo–oxazolo-derivatives and fingolimod itself, relies on engaging the S1P1 receptor, thereby
inducing lymphocyte sequestration [3]. On the other hand, it is believed that the stimulation of
S1P3, which is ubiquitously expressed throughout the body, may be associated with some adverse
reactions from fingolimod medication, such as headache, hypertension, stroke [23], cough, dyspnea,
and macular edema [24]. On the other hand, the physiological role of S1P4, which is expressed in
the immune and hematopoietic compartments, is still poorly understood and, therefore, the effects
of fingolimod mediated by S1P4, whether beneficial or detrimental, are vague. Furthermore, the net
effect of the drug binding is dependent on many factors, which include the S1P receptor repertoire
and predominant expression of a particular receptor in a cell, the collection of signaling pathways
within a cell, variations in the expression of both S1P receptors and downstream signaling proteins,
the convergence of signaling pathways initiated by different G proteins, the localization of S1P receptors
on cell membrane vs. internalized/nuclearized, etc. [25,26]. All these factors bring another level
of complexity to S1P receptor signaling. Obviously, the novel structures ST-1893 and ST-1894 are
devoid of unspecific effects through any of the other S1P receptor subtypes and, therefore, have an
additional advantage.
Although another selective S1P1 agonist, SEW2871, does not target other S1P receptors; it binds
and activates S1P1 through a combination of hydrophobic and ion–dipole interactions in the
binding pocket [27], rendering it less potent at downstream G-protein binding and kinase activation.
This tetraaromatic compound is a weak agonist that induces S1P1 internalization but then allows, similar
to S1P, receptor recycling instead of receptor degradation, which translates into rapidly reversible
lymphopenia [28]. ST-1893 and ST-1894 establish hydrogen bonds with surrounding amino-acid
residues from the receptor and likely induce a potent signal transduction which is then evidenced by a
strong reduction in the number of circulating lymphocytes in vivo. Other factors include the molecular
volume, which is larger for ST-1893 as compared to the oxazolo–oxazole compound ST-1071 [15].
This might hamper the dissociation from the receptor and translate into a higher activity as predicted
computationally, even though both had similar docking score.
S1P1 antagonism is also a valid approach to achieve a block of lymphocyte egress, and, through
the induction of lymphopenia, several competitive antagonists were demonstrated to be effective
in EAE, collagen-induced arthritis, traumatic brain injury, and cardiac allograft rejection animal
models [16,29–31]. However, S1P1 antagonism is associated with a disturbance of the endothelial
barrier integrity, especially in the lungs and skin, promoting vascular leakage, edema, and chronic
remodeling with functional impairments [32,33]. ST-1893 and ST-1894 had no effect on S1P-stimulated
receptor activation on any of the five S1P receptors, excluding any antagonism in the presence of S1P
(Figure 2A), indicating that the lymphopenic effect is solely due to a functional antagonism.
A prerequisite for the lymphocyte-depleting activity of fingolimod is the reversible and
stereoselective transformation by SK-2, in order to yield the active phospho-metabolite [34].
Contrariwise, our previously described oxazolo–oxazole substances have an advantage over fingolimod,
as they do not require SK-2-mediated phosphorylation in order to become active. Notably,
the SK-2 inhibitor ABC294640 (Yeliva®) received an orphan drug designation by the Food and
Drug Administration (FDA) due to its anticancer properties in several clinical trials (NCT01488513,
NCT02757326, NCT02229981, NCT03377179), although some of the effects observed in in vivo studies
may be attributed to off-target effects due to its low potency at SK-2 [35]. ABC294640, as well as other
SK-2 inhibitors, such as SLP120701 and ROMe, are being increasingly explored in inflammatory models,
giving promising anti-inflammatory results in acute and chronic models of ulcerative colitis, viral and
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bacterial infections, renal inflammation/fibrosis, and EAE [36–40]. Co-medication of fingolimod with
an SK-2 inhibitor, in theory, seems like a synergistic anti-inflammatory combination, but would clearly
result in therapeutic incompatibility, due to the lack of a biotransformation step for fingolimod. In this
context, using SK-2 independent structures would be mandatory, and ST-968 and ST-1071 fulfill
this criterion.
The novel morpholino-derivatives, ST-1893 and ST-1894, have a different dependence on SK-2 for
their in vivo activity (Figure 10). ST-1893 fully depends on SK-2, and, although ST-1894 decreases the
motor deficits in the absence of SK-2, the full immunomodulatory effectiveness in vivo was observed
in wild-type mice where SK-2 is normally expressed. This finding points to an inherent difference in
the oxazolo–oxazole and morpholine functional groups, which dictates whether the structure will
become a substrate of SK-2 or not. Since the crystal structure of SK-2 is still missing, predictions of
substrate binding and structure-based drug design by molecular docking studies remain vague [35].
It is also well conceivable that the ether moiety in the aliphatic chain (present in ST-1894, but not
in ST-1893) may influence the prodrug properties, as we noticed that it relatively increases the S1P1
activation, internalization rate, and lymphopenic effect in equivalent doses. Finally, the in vivo
effects depend also on other modes of biotransformation, the stability and elimination, the volume of
distribution in the secondary lymphoid tissues, etc., which warrants further studies.
In summary, here, we present two novel structures derived from fingolimod, ST-1893 and ST-1894,
which possess a selective S1P1 activation profile. Both compounds are functional antagonists that
induce sustained S1P1 internalization in cell culture and a profound lymphopenia in mice. As they
demonstrated in vivo efficacy in the EAE model, and due to their S1P1-selective nature, we speculate
that they will exhibit fewer adverse effects and have an advantage over fingolimod and siponimod,
not only in MS but also in other autoimmune diseases.
4. Materials and Methods
4.1. Chemicals and Chemical Synthesis of ST-1893 and ST-1894
All reagents used for synthesis are described in the Supplementary Materials. The chemical
synthesis of ST-1893 and ST-1894 was done by amide and ether formation with following reduction as
shown in Figure 11. Details are described in the Supplementary Materials.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 13 of 8 
 
ABC294640, as well as other SK-2 inhibitors, such as SLP120701 and ROMe, are being increasingly 
explored in inflammatory models, g ving promisi g anti-inflammatory results in acute and chronic 
models of ulcerative colitis, viral and b cterial infe tions, renal inflammation/fibrosis  and EAE [36–
40]. Co-medication of fingolimod with an SK-2 inhibitor, in theory, seems like a sy ergistic anti-
inflammatory combination, but would clearly result in therapeutic incompatibility, due to the lack of 
a biotransformation step for fingolimod. In this context, using SK-2 independent structures would be 
mandatory, and ST-968 and ST-1071 fulfill this criterion. 
The novel morpholino-derivatives, ST-1893 and ST-1894, have a different dependence on SK-2 
for their in vivo activity (Figure 10). ST-1893 fully depends on SK-2, and, although ST-1894 decreases 
the motor deficits in the absence of SK-2, the full immunomodulatory effectiveness in vivo was 
observed in wild-type mice where SK-2 is normally expressed. This finding points to an inherent 
difference in the oxazolo–oxazole and morpholine functional groups, which dictates whether the 
structure will become a substrate of SK-2 or not. Since the crystal structure of SK-2 is still missing, 
predictions of substrate binding and structure-based drug design by molecular docking studies 
remain vague [35]. 
It is also well conceivable that the ether moiety in the aliphatic chain (present in ST-1894, but not 
in ST-1893) may influence the prodrug properti s, as w  noticed that it relatively incre ses the S1P1 
activation, internalization rate, and lymphopenic effec  in equivalent doses. Finally, the i  vivo effects 
depend also on other modes of bi transformation  the stability and elimina ion, the volume of 
distrib tion in the secondary lymphoid tissues, et ., which warrants further studies. 
In summary, here, we present two novel structures derived from fingolimod, ST-1893 and ST-
1894, which possess a selective S1P1 activation profile. Both compounds are functional antagonists 
that induce sustained S1P1 internalization in cell culture and a profound lymphopenia in mice. As 
they demonstrated in vivo efficacy in the EAE model, and due to their S1P1-selective nature, we 
speculate that they will exhibit fewer adverse effects and have an advantage over fingolimod and 
siponimod, not only in MS but also in other autoimmune diseases. 
4. Materials and Methods 
4.1. Chemicals and Chemical Synthesis of ST-1893 and ST-1894 
All reagents used for synthesis are described in the Supplementary Materials. The chemical 
synthesis of ST-1893 and ST-1894 was done by amide and ether formation with following reduction 
as shown in Figure 11. Details are described in the Supplementary Materials. 
 
Figure 11. Synthesis of ST 1893 and ST-1894. (a) Triethylamine, chloroacetyl chloride, tetrahydrofuran 
(THF); (b) NaH, THF; (c) LiAlH4, THF. 
4.2. Cell Culturing 
Chinese hamster ovary (CHO)-K1 cells, which stably overexpress different human S1P1–5 
receptor subtypes, were kindly provided by Dr. Danilo Guerini (Novartis Institutes for Biomedical 
Research, Basel, Switzerland). CHO-S1P1/4/5 cells were maintained in alpha minimum essential 
medium Eagle (αMEM), while CHO-S1P2/3 were cultivated in Roswell Park Memorial Institute 
(RPMI) medium. Both media were supplemented with 10% fetal bovine serum (FBS), 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 50 µg/mL gentamycin, and 0.5 mg/mL 
G418 as a selection antibiotic. Cells were cultured in an environment of 37 °C with 5% CO2 and were 
passaged 2–3 times a week, using Trypsin-ethylenediaminetetraacetic acid (EDTA) 0.25% for 
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(THF); (b) NaH, THF; (c) LiAlH4, THF.
4.2. Cell Culturing
Chinese hamster ovary (CHO)-K1 cells, which stably overexpress different human S1P1–5
receptor subtypes, were kindly provided by Dr. Danilo Guerini (Novartis Institutes for Biomedical
Research, Basel, Switzerland). CHO-S1P1/4/5 cells were maintained in alpha minimum essential
medium Eagle (αMEM), while CHO-S1P2/3 were cultivated in Roswell Park Memorial Institute
(RPMI) medium. Both media were supplemented with 10% fetal bovine serum (FBS), 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 50 µg/mL gentamycin, and 0.5 mg/mL
G418 as a selection antibiotic. Cells were cultured in an environment of 37 ◦C with 5% CO2 and
were passaged 2–3 times a week, using Trypsin-ethylenediaminetetraacetic acid (EDTA) 0.25% for
detachment. Prior to stimulation, cells were rendered serum-free overnight with a medium consisting
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of Dulbecco’s modified Eagle medium (DMEM), 0.1 mg/mL bovine serum albumin (BSA), and 10 mM
HEPES (later on referred to as serum-free medium).
4.3. Western Blot Analysis
Western blot analysis was performed as previously described [41] by incubating membranes
with antibodies for 16 h at 4 ◦C. Commercially available antibodies used were as follows:
phospho-Thr202/Tyr204 p42/p44-MAPK (Cell Signaling, cat. no. 4377, 1:1000 dilution) and Myc-tag (Cell
Signaling, cat. no. 2276, 1:1000 dilution). IRDye® or horseradish peroxidase (HRP)-linked secondary
antibodies were used, and bands were detected and analyzed by the LI-COR Image StudioTM (v. 3.1;
LI-COR Biotechnology GmbH, Bad Homburg, Germany). Signal intensity was evaluated by ImageJ
(National Institutes of Health, USA). Polyclonal antisera against p42-MAPK and p44-MAPK were
previously generated and characterized [42] and used in a dilution of 1:3000.
4.4. RNA Extraction and Quantitative PCR Analysis
RNA extraction, complementary DNA (cDNA) synthesis, and quantitative PCR analysis were
performed as previously described [43]. Primer sequences of mouse CD3, VCAM-1, and 18S RNA
were as previously described [15,44]. The sequences for other primers were as follows: GFAP,
forward: CCAGCTTCGAGCCAAGGA, reverse: GAAGCTCCGCCTGGTAGACA; IL-1β, forward:
TGTCCTGTGTAATGAAAGACGG, reverse: TCTTGTGACCCTGAGCGAC.
4.5. S1P Receptor Activation Studies
Confluent CHO-S1P1–5 cells were incubated in serum-free medium for 20 h and then
stimulated with the indicated compounds for 10 min at 37 ◦C. Cell monolayers were washed with
phosphate-buffered saline (PBS) and lysed in lysis buffer at 4 ◦C and further processed for protein
separation by SDS-PAGE, transfer to nitrocellulose membranes, and Western blot analysis.
4.6. S1P1 Internalization Studies by ELISA
Confluent CHO-S1P1 cells in 24-well plates were starved for 20 h prior to stimulation with 3 µM
of compounds in serum-free medium. In the first experimental set-up, the stimulation was ceased after
3 h, whereas, in the second set-up, the long-term effect on receptor internalization was assessed by
stimulation for 3 h, washing, and placing in serum-free conditions for an additional 21 h. Cells were
washed three times with ice-cold PBS, fixed with 4% paraformaldehyde in PBS at room temperature
for 20 min, and blocked in 6 % (w/v) non-fat dry milk in PBS (below labeled as blocking buffer)
for 1 h. They were incubated with anti-Myc Tag antibody (1:1000 in blocking buffer) and later on
with anti-mouse HRP-linked antibody (1:5000 in blocking buffer), both for 1 h, with washing steps
in between (8 min × 3 times in PBS). After 3,3′,5,5′-tetramethylbenzidine (TMB) was added as a
substrate for the HRP, the reaction was stopped with 1 N H2SO4, and the absorbance was measured,
subtracting the blank where the primary antibody was omitted. In order to normalize with the number
of cells, we proceeded with washing, staining with 0.1% crystal violet solution in 20% methanol,
and solubilizing with 5% acetic acid. Absorbance was measured, normalized with the values from the
ELISA, and calculated to the DMSO control being 100%.
4.7. Lymphocyte Count
C57BL/6J mice were injected intraperitoneally with 5 mg/kg of ST-1893, ST-1894, or DMSO
in PBS, and, after 24 h, blood was collected in EDTA-K3-coated microvettes (Sarstedt; Sevelen,
Switzerland) with cardiac puncture under deep terminal isoflurane-induced anesthesia. The number
of lymphocytes was assessed with a Scil Vet ABCTM Hemocytometer (Scil animal care company GmbH;
Viernheim, Germany).
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4.8. Experimental Antigen-Induced Encephalomyelitis Experiments
All mice experiments were in accordance with the Swiss animal experimentation legislation
and under the license number BE50/17. Active EAE was induced in C57BL/6J mice with MOGaa35–55
emulsified in complete Freund’s adjuvant (CFA) and pertussis toxin as described previously by our
group [15]. The overall wellbeing, weight, and signs of disease were evaluated twice daily using a
four-point scoring system. Disease sign scores were as follows: 0.5: limp tail, 1: hind leg weakness and
unsteady gait, 2: hind leg paraplegia, 3: hind leg paraplegia, incontinence, and loss of lower body
control. From day 5 until day 20 post immunization, they received daily 5 mg/kg of ST-1893, ST-1894,
or DMSO in PBS via intraperitoneal injection. On day 21, blood was collected, the mice were sacrificed
and perfused with ice-cold PBS, and the CNS was extracted and snap-frozen in liquid nitrogen until
further analysis.
4.9. Organ Homogenization
The snap-frozen tissues in liquid nitrogen were homogenized using Sartorius Mikro-Dismembrator
S (Göttingen, Germany) at 3000 rpm for 1 min each. The pulverized tissues were distributed in
Eppendorf tubes; then, RNA-Solv® reagent was added and vortexed for 5 min to aid the dissolution.
Samples were centrifuged at 13,000 rpm for 10 min at 4 ◦C, and the supernatant was used for RNA
extraction and quantitative PCR analysis as described above.
4.10. Molecular Modeling
Molecular docking and energy minimization experiments were performed as disclosed in the
Supplementary Materials.
4.11. Statistical Analysis
GraphPad Prism 6 Software (San Diego, CA, USA) was used for statistical analysis and graph
representations. The statistical significance was calculated with ordinary one-way ANOVA without
matching or unpaired t-test where applicable. The level of significance was calculated with Bonferroni
correction for multiple comparisons. For the EAE experiments, the nonparametric Kruskal–Wallis
test for the area under the curve (AUC) was used. Data are depicted as means ± SD for n number of
independent experiments unless otherwise stated.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/18/6463/s1:
Figure S1. Flow of the building of the activated S1P1 model: new approach to model development; Figure S2.
Two-dimensional (2D) model of interactions of ST-1893 and its phosphate (A) or ST-1894 and its phosphate (B)
with amino-acid residues in the binding pocket of S1P1; Figure S3. Three-dimensional (3D) model of docking
of ST-1893 and its phosphate (A) or ST-1894 and its phosphate (B) into the binding pocket of S1P1; Table S1.
Interaction energies between ligand and the S1P1 receptor.
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Abbreviations
AUC area under the curve
BSA bovine serum albumin
CD3 cluster of differentiation 3
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cDNA complementary deoxyribonucleic acid
CFA complete Freund’s adjuvant
CHO Chinese hamster ovary
CNS central nervous system
DMEM Dulbecco’s modified Eagle medium
DMSO Dimethyl sulfoxide
EAE experimental antigen-induced encephalomyelitis
ECL enhanced chemiluminescence
ELISA enzyme-linked immunosorbent assay
FBS fetal bovine serum
GFAP glial fibrillary acidic protein
GPCR G-protein-coupled receptor
HRP horseradish peroxidase
IL-1β interleukin 1 beta
MAPK mitogen-activated protein kinase
αMEM minimum essential medium Eagle, alpha modification
MOG myelin oligodendrocyte glycoprotein
MS multiple sclerosis
mRNA messenger ribonucleic acid
PBS phosphate-buffered saline
PECAM-1 platelet and endothelial cell adhesion molecule 1
PTX pertussis toxin
S1P sphingosine 1-phosphate
S1PR sphingosine 1-phosphate receptor
SK sphingosine kinase
TMB 3,3’,5,5’-tetramethylbenzidine
VCAM-1 vascular cell adhesion molecule 1
wt wild type
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